Treat and Extend Dosing Regimen with Anti-vascular Endothelial Growth Factor Agents for Neovascular Age-related Macular Degeneration
|
|
- John Stanley
- 5 years ago
- Views:
Transcription
1 REVIEW ARTICLE Treat and Extend Dosing Regimen with Anti-vascular Endothelial Growth Factor Agents for Neovascular Age-related Macular Degeneration Karen M. Wai, Rishi P. Singh Department of Ophthalmology, Cole Eye Institute, Cleveland Clinic, Cleveland, Ohio, USA Abstract Corresponding Author: Karen M. Wai, Cole Eye Institute, Cleveland Clinic, 2022 East 105 th Street, Cleveland, OH 44106, USA. Received: 28-February-2018 Accepted: 03-April-2018 Published: 17-April-2018 Anti-vascular endothelial growth factor (anti-vegf) agents are the mainstay of therapy for treatment of neovascular age-related macular degeneration (nvamd), one of the leading causes of blindness in the developed world. There have been a variety of different treatment regimens that have been examined for the administration of anti- VEGF therapies, including continuous fixed dosing, pro re nata administration, and treat and extend (TAE) protocols. There is no clear consensus on which dosing regimen optimizes visual and anatomical outcomes while accounting for factors such as cost and patient burden. Based on recent surveys in 2014 and 2017 by the American Society of Retina Specialists (ASRS), the majority of ophthalmology providers are utilizing TAE protocol for anti-vegf dosing for the management of nvamd. Although there are a number of clinical trials that have examined TAE dosing, the ALTAIR study is the first, large, prospective randomized controlled trial to compare two different TAE protocols utilizing the anti-vegf agent aflibercept for nvamd. The ALTAIR study, in conjunction with other previous clinical trials, suggests that TAE protocol with aflibercept is an effective anti-vegf dosing regimen for patients with nvamd as it produces good visual gains and minimizes cost and burden for the patient. Keywords: Anti-vascular endothelial growth factor, Neovascular age-related macular degeneration, Treat and extend INTRODUCTION T he introduction of anti-vascular endothelial growth factor (anti-vegf) therapy has revolutionized the management for neovascular age-related macular degeneration (nvamd), the leading cause of irreversible blindness for those over 50 years of age in the developed world. [1,2] nvamd is characterized by the growth of abnormal Access this article online Quick Response Code: Website: DOI: / blood vessels within the macula and can lead to significant and severe vision loss. The cytokine VEGF has been shown to promote angiogenesis and vascular permeability; [3] inhibition of this cytokine with anti-vegf agents such as bevacizumab, ranibizumab, and aflibercept has proven to be an effective treatment for nvamd. There has been a variety of different treatment regimens utilizing anti-vegf agents; previous randomized control trials have examined the administration of anti-vegf agents in various dosing regimens, such as a continuous fixed dosing, pro re nata (PRN), and treat and extend (TAE) protocols. Fixed dosing regimens involve the administration of injections at pre-determined set intervals (i.e., monthly, bimonthly, and quarterly). The MARINA, [2] ANCHOR, [4] VIEW 1, and VIEW 2 [5] trials showed the efficacy of ranibizumab and aflibercept This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms. American Journal of Ophthalmic Clinical Trials (1) 1
2 administered as a continuous regimen of injections given monthly over a period of 24 months for patients with nvamd. The PIER [6] and EXCITE [7] trials examined the efficacy of ranibizumab injections administered on a quarterly basis. Both the PIER and EXCITE trials determined quarterly injections were inferior to a monthly dosing regimen for visual acuity gains. In contrast, a PRN dosing regimen is individualized on the basis of the clinical examination and the presence of fluid; retreatment is determined based on a decrease in visual acuity or evidence of disease activity. The SAILOR [8] trial examined ranibizumab administered on a PRN basis, while the CATT [9] trial compared bevacizumab and ranibizumab administered PRN versus fixed monthly dosing. The above studies showed that quarterly and PRN regimens led to less frequent monitoring and dosing for patients. The CATT [9] trial showed a larger, though insignificantly different, letter gain in the fixed monthly dosing arm compared to the PRN arm. Contrarily, the PIER and EXCITE studies showed a significant decrease in visual acuity gain in the quarterly arm compared to the monthly arm. [6,7] These studies showed that a less frequent dosing regimen such as PRN may be a viable alternative to monthly dosing though quarterly injections are unsatisfactory to preserve visual outcomes. ranibizumab injections. [10] The patients in this study received Furthermore, the HARBOR trial studied 2-year outcomes for nvamd patients who were treated PRN after 3 months of anywhere from 3 to 24 injections over a 24 month period, with the median number of injections patients needed by the month 24 was 14 (n = 237). The results from this study favor the individualized unique response to anti-vegf agents, and perhaps, the need for a regimen that is more tailored to the patient. As evidenced in the previous studies, it is likely that a fixed, frequent dosing regimen will lead to overtreatment in some patients. Further drawbacks to a fixed dosing regimen include higher costs for potentially unnecessary treatment and a burden for the patient given the increased frequency of visits. With a greater number of injections, it also increases the risk for infection, glaucoma, [11] and possibly atrophy. [12] On the other hand, a PRN regimen may allow for the recurrence of neovascular leakage and growth for patients with nvamd. Multiple recurrences can lead to further progression of the disease, which could lead to poor long-term visual outcomes in some patients. There has been no clear consensus as for which regimen is most efficacious and cost-effective for patient outcomes. In routine clinical practice, practitioners use a variety of dosing regimens to treat nvamd. The American Society of Retina Specialists (ASRS) survey in 2014 showed that the majority of clinicians practice with TAE protocol (78%), though some report using PRN protocol (16%), with a minority using a fixed regimen (2%). [13] Furthermore, in 2017, the ASRS American Journal of Ophthalmic Clinical Trials (1) 2 survey reported an increasing proportion of clinicians (70.9%) are utilizing a TAE dosing regimen to treat nvamd patients once they have achieved dryness on their optical coherence tomography (OCT) scan. [14] nvamd is a heterogeneous disease with a variable natural history, and patients have differing response to intravitreal injections. Fixed monthly treatments are not suitable for every individual, as the degree of VEGF suppression varies between patients. A treatment regimen that physicians are utilizing more frequently in routine clinical practice is TAE. [13,14] TAE protocol involves monthly treatment with anti-vegf until the patient is considered dry and with stable visual acuity. The macula is considered dry when there is no visible subretinal fluid or intraretinal cysts and the central retinal subfield thickness is no greater than 2 standard deviations from the normal of the OCT system used. If the patient is considered dry with stable vision, then their treatment interval can be extended appropriately by a predetermined interval. Furthermore, if the fluid recurs or their visual acuity worsens, their treatment interval is then decreased. TAE dosing is variable and therefore individualized while also allowing the patient to receive proactive continuous treatment. This review examines the major studies in the literature that have utilized TAE therapy, particularly focusing on the ALTAIR study. The ALTAIR study is the first large prospective randomized controlled trial to critically compare different TAE regimens with aflibercept. ALTAIR STUDY The ALTAIR study is a multicenter randomized open-label Phase 4 study performed in Japan at 40 clinical sites to assess two different approaches of the TAE dosing regimen. [15] Although there are a number of other studies that have examined TAE regimens, previously there have been no published prospective large-scale clinical studies of patients receiving the anti-vegf agent aflibercept using the TAE protocol or that have directly compared multiple TAE regimens. Inclusion criteria for the study included adults aged over 50 years with treatment-naive nvamd, active subfoveal CNV lesions seen on fluorescein angiography, and BCVA of 25 to 73 ETDRS letters (approximately 20/40-20/320 Snellen equivalent) in the study eye. 3 monthly doses of intravitreal aflibercept injections were given to each patient. Patients were then randomized to either 2-week or 4-week treatment intervals for injections. Main outcome measured was mean change in BCVA from baseline to week 52. [15] 255 patients were included in the study. 124 patients were in the 2-week adjustment group and 123 patients were in the 4-week adjustment group. Patients were extended if no fluid was seen on examination, maintained at their interval if there was residual but decreased fluid, and had a shortened interval
3 if there was persistent unchanged or new fluid. The minimum interval for patients in week 16 of the study and beyond was 8 weeks, and the maximum extended interval was 16 weeks. [15] As summarized in (Table 1), the 2-week extension group has a mean gain of 9.0 letters, and the 4-week extension group had a mean gain of 8.4 letters at 52 weeks. 32.5% of patients in the 2-week adjustment group and 30.9% of patients in the 4-week adjustment group gained 15 ETDRS letters by 52 weeks. The last interval before the week 52 was an average of 10.7 weeks for the 2-week extension group and 11.8 weeks for the 4-week extension group. In the 2-week extension group, the last interval was >8 weeks for 72 patients (58.5%), >12 weeks for 52 patients (42.3%), and 16 weeks for zero patients. In the 4-week extension group, the last interval was >8 weeks for 74 patients (60.2%), >12 weeks for 61 patients (49.6%), and 16 weeks for 50 patients (40.7%). [15] The 2-week extension group had an average of 7.2 injections over 52 weeks, while the 4-week extension group had an average of 6.9 injections. Based on their last visit within the 52 weeks, the length of the next scheduled interval for patients in the 2-week extension group was >8 weeks for 76 patients (68.5%), >12 weeks for 63 patients (56.8%), and 16 weeks for 39 patients (35.1%). For the patients in the 4-week extension group, the length of the next scheduled interval was >8 weeks for 76 patients (65.5%), >12 weeks for 67 patients (57.8%), and 16 weeks for 47 patients (40.5%). [15] COMPARISON TAE STUDIES A number of other studies, including ALTAIR, have examined the efficacy of TAE therapy. There have been some prospective studies though the majority have been retrospective and examined the anti-vegf agents such as ranibizumab and bevacizumab. The results of the various TAE studies are also summarized in (Table 2). Prospective TAE studies with aflibercept In addition to ALTAIR, one smaller study looked at the use of aflibercept to treat nvamd using a TAE protocol, Aflibercept TAE for Less frequent Administration Study. This was a prospective study with 31 nvamd patients over a 2-year period. [16] Patients received a mean number of 8 injections over the 1 st year and 6.5 injections in the 2 nd year. Comparable to the results of the ALTAIR study, 75% of the patients in the study had their treatment interval extended to 8 or more weeks while 38% had their treatment interval extended to 12 or more weeks. Prospective studies with TAE arm with ranibizumab or bevacizumab The LUCAS study examined TAE regimens using anti- VEGF agents ranibizumab and bevacizumab in a large prospective study with 432 patients, where patients were extended by 2 weeks at a time with a maximum interval of 12 weeks. [17] Both agents produced comparable gains in ETDRS letters (8.2 letters for ranibizumab and 8.0 for bevacizumab) and similar decreases in retinal thickness (120 µm for ranibizumab and 109 µm for bevacizumab). There was a statistically significant, though small difference, in the number of injections (8 for ranibizumab and 8.8 for bevacizumab) at 12 months. This study showed the similar efficacies of using a TAE dosing regimen with ranibizumab and bevacizumab to treat nvamd. The TREND study is a large prospective study with 650 patients that examined TAE versus monthly dosing using Table 1: Summarized results of the ALTAIR study Metrics measured in ALTAIR study 2 week extension group 4 week extension group ETDRS gain in 52 weeks % who gained 15 ETDRS letters in 52 weeks 32.5% 30.9% Average number of injections in 52 weeks Length of last interval in weeks before week Number of patients with last interval >8 weeks 72 (58.5%) 74 (60.2%) Number of patients with last interval >12 weeks 52 (42.3%) 49.6 (40.7%) Number of patients with last interval 16 weeks 0 (0%) 50 (40.7%) Length of next scheduled interval in weeks determined at last visit Number of patients with next interval determined 76 (68.5%) 76 (65.5%) as >8 weeks Number of patients with next interval determined 63 (56.8%) 67 (57.8%) as >12 weeks Number of patients with next interval determined as 16 weeks 39 (35.1%) 47 (40.5%) American Journal of Ophthalmic Clinical Trials (1) 3
4 Table 2: Summarized results of studies with TAE arm Study Number of patients in TAE ar m Study design VA gain at 52 weeks (letters) ranibizumab. [18] Their study protocol extended patients out by 2 weeks at a time, with a maximum of a 12-week treatment interval. The study showed that TAE dosing with ranibizumab was non-inferior (P < 0.001) and had clinically comparable results in visual acuity (6.2 letters vs. 8.1 letters, respectively) compared to monthly dosing after 52 weeks. The TREX-AMD study is a prospective study comparing patients treated with monthly dosing versus those treated with TAE protocol. [19] This study used an extension interval of 2 weeks after 3 monthly loading doses of ranibizumab, with a maximum extension interval of 12 weeks. Of the patients in the TAE protocol (n = 40), 68% of patients began interval extension after their mandatory injections or within 1 visit, while 10% of patients were never able to be extended. Their 1-year results showed patients on the monthly regimen gained an average of 9.2 letters while the patients on the TAE protocol gained an average of 10.5 letters, though the difference was not statistically significant (P = 0.60). The mean maximum extension for patients on the TAE protocol was 8.4 weeks after the first 3 monthly doses. Retrospective studies with TAE arm A retrospective study performed in Paris by Oubraham et al. compared a PRN protocol (n = 52) versus TAE protocol (n = 38) with ranibizumab. [20] The results favored the TAE group as there was a significant difference in gain of letters (10.8 letters for TAE vs. 2.3 letters for PRN). Although more injections were needed (7.8 for TAE vs. 5.2 for PRN), the TAE group had superior visual outcomes compared to the PRN group. The UK AMD/DR EMR Report I retrospectively compared outcomes using the national electronic medical record from 21 United Kingdom hospitals of 1884 eyes between American Journal of Ophthalmic Clinical Trials (1) 4 Mean number of injections at 52 weeks % of patients extending >8 weeks ranibizumab given PRN and aflibercept given either with fixed or TAE protocols over 12 months. [21] Aflibercept achieved greater gains in visual acuity at 1 year compared to ranibizumab though the observed changes were relatively small (4.1 letter difference). However, it was suggested that the increased gain in letters in the aflibercept cohort was due to greater frequency of treatment (7 aflibercept injections vs. 5.8 ranibizumab injections) despite a decreased number of visits (9.0 visits in the aflibercept cohort and 10.8 visits in the ranibizumab cohort). The results of the aflibercept cohort in this study are comparable to the results of ALTAIR. This study also raises the possibility that ranibizumab could be given with fixed or TAE protocols to achieve similar visual outcomes. DISCUSSION % of patients extending >12 weeks ALTAIR 255 Prospective ALTAIR 2 week arm ALTAIR 4 week arm ATLAS 31 Prospective LUCAS 432 Prospective Bevacizumab arm Ranibizumab arm Trend 320 Prospective TREX AMD 40 Prospective (extended>11 weeks) Oubraham study 38 Retrospective Not recorded Not recorded UK AMD 942 Retrospective Not recorded Not recorded In comparison to these studies, the ALTAIR study is the first to critically compare different TAE protocols and showed that both the 2- and 4-week extension protocols for TAE regimens improved visual and anatomical outcomes through week 52. The majority of patients in both the 2- and 4-week extension groups of ALTAIR achieved >12 week extension intervals for their anti-vegf injections. Zero patients in the 2-week extension group were extended to 16 weeks; it is important to recognize that patients in the 2-week extension arm, in comparison to the 4-week extension arm, were unable to be fully extended to a 16-week treatment interval within the 52-week period due to the protocol guidelines of extending only 2-week periods at a time. Overall, these findings demonstrate the efficacy of TAE regimens with both 2- and 4- week adjustment periods, though perhaps a 4-week extension interval is more preferable as it requires less injection and clinic burden to the patient. ALTAIR is the first large prospective randomized controlled study for nvamd to evaluate two separate TAE regimens using aflibercept.
5 Some drawbacks to the ALTAIR study may include the generalizability of the study. Because this study was carried out in the Japanese population, it may include a higher rate of patients with polypoidal choroidal vasculopathy than when compared to other populations. [22] Furthermore, ALTAIR s study protocol had a maximum treatment extension interval of 16 weeks; treatment interval extension beyond 12 weeks is relatively uncommon in other trials, and it may be difficult to compare this trial to other clinical studies. Further analysis of disease activity with fluorescein angiography or optical coherence tomography angiography at various time points may provide more data and allow investigators to determine why particular patients are able to be extended out further than other patients based on a patient s baseline demographics. Overall, there is a lack of long-term assessments of patients with TAE regimens. In light of studies demonstrating loss of vision after the initial visual gains 5 7 years from treatment initiation, [23,24] it would also be important to confirm that TAE regimens do not perform in the same fashion. Other drawbacks to TAE regimens include the degree of variability for fluid recurrences and how TAE protocols can differ for how patients treatment intervals were extended or shortened. [18,19] CONCLUSIONS TAE is a useful dosing strategy for nvamd given the variable nature of the disease and the range of responses that patients have to VEGF suppression. There has been some disparity between results in visual outcomes observed in randomized controlled trials and those of routine clinical practice. The dosing interval in TAE can be carefully adjusted based on a patient s functional status and their anatomical conditions within the disease progression. For providers, TAE may be a preferred dosing regimen for nvamd compared to other dosing regimens such as PRN and fixed dosing. TAE protocol allows for an individualized therapy that avoids both under- and over-treatment for patients. As evidenced in the ALTAIR study, an interval extension of 4 weeks may be sufficient to monitor treatments. This allows for less burden for patients as well as cost effectiveness. Unlike the monthly dosing regimens, a major benefit to the TAE protocol is that it identifies patients who do not need continuous monitoring and ongoing injections. In addition, unlike PRN regimens, TAE can minimize setbacks and recurrences of fluids while maximizing long-term visual outcomes. ALTAIR and other previous studies examining TAE dosing have consistently showed a gain of about 8 10 letters with the use of anti-vegf agents as well as an overall reduction in treatment burden and frequency of visits. In routine clinical practice, individualized dosing using TAE protocol with an interval extension of 4 weeks may be sufficient to monitor and treat a patient s nvamd disease progression while minimizing the frequency and cost of treatment. REFERENCES 1. Congdon N, O Colmain B, Klaver CC, Klein R, Muñoz B, Friedman DS, et al. Causes and prevalence of visual impairment among adults in the united states. Arch Ophthalmol 2004;122: Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355: Kliffen M, Sharma HS, Mooy CM, Kerkvliet S, de Jong PT. Increased expression of angiogenic growth factors in age-related maculopathy. Br J Ophthalmol 1997;81: Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006;355: Heier JS, Brown DM, Chong V, Korobelnik JF, Kaiser PK, Nguyen QD, et al. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology 2012;119: Regillo CD, Brown DM, Abraham P, Yue H, Ianchulev T, Schneider S, et al. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER study year 1. Am J Ophthalmol 2008;145: Schmidt-Erfurth U, Eldem B, Guymer R, Korobelnik JF, Schlingemann RO, Axer-Siegel R, et al. Efficacy and safety of monthly versus quarterly ranibizumab treatment in neovascular age-related macular degeneration: The EXCITE study. Ophthalmology 2011;118: Boyer DS, Heier JS, Brown DM, Francom SF, Ianchulev T, Rubio R. A phase IIIb study to evaluate the safety of ranibizumab in subjects with neovascular age-related macular degeneration. Ophthalmology 2009;116: Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, Jaffe GJ. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 2011;364: Ho AC, Busbee BG, Regillo CD, Wieland MR, Van Everen SA, Li Z, et al. Twenty-four-month efficacy and safety of dd0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration. Ophthalmology 2014;121: Dedania VS, Bakri SJ. Sustained elevation of intraocular pressure after intravitreal anti-vegf agents: What is the evidence? Retina 2015;35: Grunwald JE, Pistilli M, Ying GS, Maguire MG, Daniel E, Martin DF. Growth of geographic atrophy in the comparison of age-related macular degeneration treatments trials. Ophthalmology 2015;122: American Journal of Ophthalmic Clinical Trials (1) 5
6 13. Pollack JS. Preferences and trends survey. Am Soc Retinal Spec Available from: [Last accessed on 2018 Jan 02]. 14. Stone TW, editor. ASRS 2017 Preferences and Trends Membership Survey. Chicago, IL: American Society of Retina Specialists; Ohji M, Okada AA, Takahashi K, Kobayashi M, Terano Y. Two Different Treat and Extend Dosing Regimens of Intravitreal Afibercept for wamd in Japanese Patients: 52 Week Results of the ALTAIR Study. Barcelona: Euretina Meeting; Regillo CD, Palioura S, Galor A, Garg N, Nanji A, Joag M, et al. Late Breaker Paper Presentation at the AAO Retina Sub Day Meeting, Las Vegas; Berg K, Pedersen TR, Sandvik L, Bragadóttir R. Comparison of ranibizumab and bevacizumab for neovascular age-related macular degeneration accord to LUCAS treat-and-extend protocol. Ophthalmology 2015;122: Silva R, Berta A, Larsen M, Macfaden W, Feller C, Monés J. Treat-and-extend versus monthly regimen in neovascular age-related macular degeneration: Results with ranibizumab from the TREND study. Ophthalmology 2018;125: Wykoff CC, Croft DE, Brown DM, Wang R, Payne JF, Clark L, et al. Prospective trial of treat-and-extend versus monthly dosing for neovascular age-related macular degeneration: TREX-AMD 1-year results. Ophthalmology 2015;122: Oubraham H, Cohen SY, Samimi S, Marotte D, Bouzaher I, Bonicel P, et al. Inject and extend dosing versus dosing as needed: A comparative retrospective study of ranibizumab in exudative age-related macular degeneration. Retina 2011;31: Lee AY, Lee CS, Egan CA, Bailey C, Johnston RL, Natha S, et al. UK AMD/DR EMR REPORT IX: Comparative effectiveness of predominantly as needed (PRN) ranibizumab versus continuous aflibercept in UK clinical practice. Br J Ophthalmol 2017;101: Wong CW, Wong TY, Cheung CM. Polypoidal choroidal vasculopathy in Asians. J Clinc Med 2015;4: Rofagha S, Bhisitkul RB, Boyer DS, Sadda SR, Zhang K; SEVEN-UP Study Group. Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: A multicenter cohort study (SEVEN-UP). Ophthalmology 2013;120: Gillies MC, Campain A, Barthelmes D, et al. Long-term outcomes of treatment of neovascular age-related macular degeneration: Data from an observation study. Ophthalmology 2015;122: How to cite this article: Wai KM, Singh RP. Treat and Extend Dosing Regimen with Anti-vascular Endothelial Growth Factor Agents for Neovascular Agerelated Macular Degeneration. Am J Ophthalmic Clin Trails 2018, 1(1) 1-6. American Journal of Ophthalmic Clinical Trials (1) 6
Outcomes of Anti-VEGF Therapy for Neovascular Age-Related Macular Degeneration in Routine Clinical Practice
Outcomes of Anti-VEGF Therapy for Neovascular Age-Related Macular Degeneration in Routine Clinical Practice Andrew A. Moshfeghi, MD, MBA 1 ; John D. Pitcher, MD 2,3 ; Genevieve Lucas, B. Comm. 4 ; Nick
More informationManagement of Neovascular AMD
Kapusta AMD Part 1 Management of Neovascular AMD Dr. Michael A. Kapusta, MD, FRCSC Ophthalmologist in Chief Jewish General Hospital Vitreoretinal Surgeon 1 FINANCIAL DISCLOSURES Consulting honoraria Bayer,
More informationOptimizing the Anti-VEGF Treatment Strategy for Neovascular Age-Related Macular Degeneration: From Clinical Trials to Real-Life Requirements
Perspective DOI: 10.1167/tvst.4.3.6 Optimizing the Anti-VEGF Treatment Strategy for Neovascular Age-Related Macular Degeneration: From Clinical Trials to Real-Life Requirements Irmela Mantel 1,2 1 Department
More informationLondon Medicines Evaluation Network Review
London Medicines Evaluation Network Review Evidence for initiating intravitreal bevacizumab for the management of wet age-related macular degeneration (wet-amd) in eyes with vision better than 6/12 November
More informationClinical Trials Related to Age Related Macular Degeneration
Clinical Trials Related to Age Related Macular Degeneration Kirti Singh MD, DNB, FRCS Kirti Singh MD, DNB, FRCS, Pooja Jain MBBS, Nitasha Ahir MBBS, Divya Jain MD, DNB Guru Nanak Eye Centre, Maulana Azad
More informationOutcomes of Intravitreal Anti-VEGF Therapy for Diabetic Macular Edema in Routine Clinical Practice
Outcomes of Intravitreal Anti-VEGF Therapy for Diabetic Macular Edema in Routine Clinical Practice John D. Pitcher, MD 1,2 ; Andrew A. Moshfeghi, MD 3 ; Genevieve Lucas, B. Comm. 4 ; Nick Boucher, BS 4
More informationA Treat and Extend Regimen Using Ranibizumab for Neovascular Age-Related Macular Degeneration
A Treat and Extend Regimen Using Ranibizumab for Neovascular Age-Related Macular Degeneration Clinical and Economic Impact Omesh P. Gupta, MD, MBA, Gary Shienbaum, MD, Avni H. Patel, MD, Christopher Fecarotta,
More informationClinical Study Fixed Monthly versus Less Frequent Ranibizumab Dosing and Predictors of Visual Response in Exudative Age-Related Macular Degeneration
Ophthalmology Volume 12, Article ID 69641, 8 pages doi:1.1155/12/69641 Clinical Study Fixed Monthly versus Less Frequent Ranibizumab Dosing and Predictors of Visual Response in Exudative Age-Related Macular
More informationSUMMARY. Heather Casparis, MD,* and Neil M. Bressler, MD MARINA AND ANCHOR
The following are summaries of selected presentations and posters from the American Society of Retina Specialists and European VitreoRetinal Society Annual Meeting held September 9 13, 2006, in Cannes,
More informationUse of Aflibercept in cases of recurrent or refractory neovascular AMD previously treated with other antiangiogenic drug: anatomo-functional outcomes
Use of Aflibercept in cases of recurrent or refractory neovascular AMD previously treated with other antiangiogenic drug: anatomo-functional outcomes Daniel E. Charles, MD, Martin Charles, MD, Gisela Jelusich,
More informationInstudies of vascular endothelial growth factor
MONITORING THERAPEUTIC EFFICACY IN THE ANTI-VEGF ERA* SriniVas R. Sadda, MD ABSTRACT One of the most important questions with vascular endothelial growth factor (VEGF) inhibitors for age-related macular
More informationCLINICAL STUDY. S Borooah 1, VS Jeganathan 1, A-M Ambrecht 1, D Oladiwura 2, M Gavin 2, B Dhillon 1 and P Cackett 1
(2015) 29, 1156 1161 2015 Macmillan Publishers Limited All rights reserved 0950-222X/15 www.nature.com/eye CLINICAL STUDY Long-term visual outcomes of intravitreal ranibizumab treatment for wet age-related
More informationWet AMD. dept headline headline. headline headline. From Start to Finish
Wet AMD dept headline headline From Start to Finish headline headline Deck Anti-VEGF therapy for patients with wet AMD is a standard of care that saves sight for thousands of people each year. dept byline
More informationThese issues are covered in more detail below.
26.3.07 Comments from Novartis on the Assessment Report for the Health Technology Appraisal of Pegaptinib and Ranibizumab for the treatment of age-related macular degeneration In general we feel that the
More informationWe are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists. International authors and editors
We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists 3,700 108,500 1.7 M Open access books available International authors and editors Downloads Our
More informationMacular Morphology and Visual Acuity in the Comparison of Age-related Macular Degeneration Treatments Trials
Macular Morphology and Visual Acuity in the Comparison of Age-related Macular Degeneration Treatments Trials Glenn J. Jaffe, MD, 1 Daniel F. Martin, MD, 2 Cynthia A. Toth, MD, 1 Ebenezer Daniel, MPH, PhD,
More informationOpthea Initiates OPT-302 Diabetic Macular Edema Clinical Trial
ASX and Media Release 3 January 2018 Opthea Initiates OPT-302 Diabetic Macular Edema Clinical Trial Melbourne, Australia; January 3 2018 Opthea Limited (ASX:OPT), a late stage biopharmaceutical company
More informationSubgroup Analysis of the MARINA Study of Ranibizumab in Neovascular Age-Related Macular Degeneration
Subgroup Analysis of the MARINA Study of in Neovascular Age-Related Macular Degeneration David S. Boyer, MD, 1 Andrew N. Antoszyk, MD, 2 Carl C. Awh, MD, 3 Robert B. Bhisitkul, MD, PhD, 4 Howard Shapiro,
More informationFive-year Outcomes of Ranibizumab in Neovascular Age-related Macular Degeneration: Real Life Clinical Experience
pissn: 1011-8942 eissn: 2092-9382 Korean J Ophthalmol 2017;31(5):424-430 https://doi.org/10.3341/kjo.2016.0125 Original Article Five-year Outcomes of Ranibizumab in Neovascular Age-related Macular Degeneration:
More informationTreatment practice in the
Strategies for managing neovascular AMD and in routine clinical care BY ROD MCNEIL Treatment practice in the management of neovascular age-related macular degeneration (AMD) and diabetic macular oedema
More informationWestborg, Inger ; Albrecht, Susanne; Rosso, Aldana. Published in: Retina DOI: /IAE
RISK FOR LOW VISUAL ACUITY AFTER 1 AND 2 YEARS OF TREATMENT WITH RANIBIZUMAB OR BEVACIZUMAB FOR PATIENTS WITH NEOVASCULAR AGERELATED MACULAR DEGENERATION Westborg, Inger ; Albrecht, Susanne; Rosso, Aldana
More informationDiabetic Retinopathy: Recent Advances in Treatment and Treatment Approaches
Diabetic Retinopathy: Recent Advances in Treatment and Treatment Approaches Dr. David Wong Associate Professor Retina Specialist, Department of Ophthalmology & Vision Sciences, University of Toronto, Canada
More informationIntraocular Radiation Therapy for Age-Related Macular Degeneration
Medical Policy Manual Medicine, Policy No. 134 Intraocular Radiation Therapy for Age-Related Macular Degeneration Next Review: April 2019 Last Review: June 2018 Effective: August 1, 2018 IMPORTANT REMINDER
More informationDigital Journal of Ophthalmology, Vol. 21 Digital Journal of Ophthalmology, Vol. 21
Original Article Feasibility and efficacy of a mass switch from ranibizumab (Lucentis) to bevacizumab (Avastin) for treatment of neovascular age-related macular degeneration Michael T. Andreoli, MD, a,b
More informationPersistent Macular Thickening After Ranibizumab Treatment for Diabetic Macular Edema With Vision Impairment
9:30 AM Persistent Macular Thickening After Ranibizumab Treatment for Diabetic Macular Edema With Vision Impairment Lee Jampol, MD OBJECTIVE To assess subsequent visual and anatomic outcomes of eyes with
More informationComputerized Model of Cost-Utility Analysis for Treatment of Age-Related Macular Degeneration
Computerized Model of Cost-Utility Analysis for Treatment of Age-Related Macular Degeneration E. C. Fletcher, MRCOphth, 1 R. J. Lade, PhD, MBA, 2 T. Adewoyin, MRCOphth, 1 N. V. Chong, FRCOphth, MD 1 Purpose:
More informationGood News for The Macular Generation. Dr Andrew Thompson FRANZCO
Good News for The Macular Generation Dr Andrew Thompson FRANZCO Anti-VEGFs for wet MD are one of the greatest advances in medicine in past decade Prof. Gary Brown Director Wills Eye Institue Retina Service
More informationOptical Coherence Tomography Monitoring Strategies for A-VEGF Treated Age-Related Macular Degeneration: An Evidence-Based Analysis
Optical Coherence Tomography Monitoring Strategies for A-VEGF Treated Age-Related Macular Degeneration: An Evidence-Based Analysis G Pron August 2014 Ontario Health Technology Assessment Series; Vol. 14:
More informationAflibercept in wet age-related macular degeneration: a perspective review
446007TAJ342040622312446007M Ohr and PK KaiserTherapeutic Advances in Chronic Disease 2012 Therapeutic Advances in Chronic Disease Review ibercept in wet age-related macular degeneration: a perspective
More informationAnti VEGF Agents in Retinal Disorders Current Scenario
Retina Anti VEGF Agents in Retinal Disorders Current Scenario Charu Gupta MS Charu Gupta MS, Cyrus M. Shroff MD Shroff Eye Centre, New Delhi T is a group of proteins involved in the regulation of angiogenesis,
More informationNEOVASCULAR AGE-RELATED MACULAR DEGENERation
Randomized, Double-Masked, -Controlled Trial of Ranibizumab for Neovascular Age-Related Macular Degeneration: PIER Study Year 2 PREMA ABRAHAM, HUIBIN YUE, AND LAURA WILSON PURPOSE: To evaluate efficacy
More informationFEP Medical Policy Manual
FEP Medical Policy Manual Last Review: September 2016 Next Review: September 2017 Related Policies 6.01.10 Stereotactic Radiosurgery and Stereotactic Body Radiotherapy 8.01.10 Charged-Particle (Proton
More informationShort-term outcomes of switching anti-vegf agents in eyes with treatment-resistant wet AMD
Batioglu et al. BMC Ophthalmology (2015) 15:40 DOI 10.1186/s12886-015-0025-z RESEARCH ARTICLE Open Access Short-term outcomes of switching anti-vegf agents in eyes with treatment-resistant wet AMD Figen
More informationANTIVASCULAR ENDOTHELIAL GROWTH FACTOR
THE ROLE OF RANIBIZUMAB * Michael L. Klein, MD ABSTRACT The positive 1-year results of ranibizumab trials reported at the 23rd Annual Meeting of the American Society of Retina Specialists have generated
More informationThere are no published randomized, double-blind trials comparing aflibercept to other therapies in neovascular AMD.
Subject: Eylea (aflibercept) Original Effective Date: 7/11/2014 Policy Number: MCP-191 Revision Date(s): 10/11/2016 Review Date(s): 12/16/2015; 10/11/2016, 6/22/2017, 7/10/2018 DISCLAIMER This Medical
More informationFEP Medical Policy Manual
FEP Medical Policy Manual Last Review: September 2016 Next Review: September 2017 Related Policies 9.03.20 Intraocular Radiation Therapy for Age-Related Macular Degeneration Photodynamic Therapy for Choroidal
More informationAlthough photocoagulation and photodynamic PROCEEDINGS PEGAPTANIB SODIUM FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION *
PEGAPTANIB SODIUM FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION Evangelos S. Gragoudas, MD ABSTRACT In December 24, the US Food and Drug Administration (FDA) approved pegaptanib sodium. Pegaptanib
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationBayer to showcase latest Ophthalmology research at EURETINA 2017
Investor News Not intended for U.S. and UK Media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com 17 th European Society of Retina Specialists (EURETINA) Congress Bayer to showcase
More informationOriginal Article Ranibizumab as needed therapy for wet age-related macular degeneration combined with serous pigment epithelial detachment
Int J Clin Exp Med 2016;9(7):13650-13656 www.ijcem.com /ISSN:1940-5901/IJCEM0026582 Original Article Ranibizumab as needed therapy for wet age-related macular degeneration combined with serous pigment
More informationClinical Study Effects of Intravitreal Ranibizumab Injection on Chinese Patients with Wet Age-Related Macular Degeneration: 5-Year Follow-Up Results
Ophthalmology Volume 2016, Article ID 6538192, 5 pages http://dx.doi.org/10.1155/2016/6538192 Clinical Study Effects of Intravitreal Ranibizumab Injection on Chinese Patients with Wet Age-Related Macular
More informationNATURAL COURSE OF PATIENTS DISCONTINUING TREATMENT FOR AGE-RELATED MACULAR DEGENERATION AND FACTORS ASSOCIATED WITH VISUAL PROGNOSIS
NATURAL COURSE OF PATIENTS DISCONTINUING TREATMENT FOR AGE-RELATED MACULAR DEGENERATION AND FACTORS ASSOCIATED WITH VISUAL PROGNOSIS JAE HUI KIM, MD,* YOUNG SUK CHANG, MD, JONG WOO KIM, MD* Purpose: To
More informationFrom Outdated to Updated: A Review of Important Clinical Trials in Ocular Disease from 2014
From Outdated to Updated: A Review of Important Clinical Trials in Ocular Disease from 2014 1. This course is designed to review the important ophthalmic literature that was released between October 2013
More informationRoutine versus As-Needed Bevacizumab with 12-Weekly Assessment Intervals for Neovascular Age-Related Macular Degeneration
Routine versus As-Needed Bevacizumab with 12-Weekly Assessment Intervals for Neovascular Age-Related Macular Degeneration 92-Week Results of the GMAN Trial Sajjad Mahmood, FRCOphth, 1,3 Stephen A. Roberts,
More informationMacular edema (ME) is the most common
MANAGEMENT OF RETINAL VEIN OCCLUSIONS * Peter A. Campochiaro, MD ABSTRACT Macular edema (ME) is the most common cause of reduced vision in patients with retinal vein occlusions (RVOs). The primary cause
More informationSophie C. Böhni 1*, Mario Bittner 1, Jeremy P. Howell 1, Lucas M. Bachmann 2, Livia Faes 2 and Martin K. Schmid 1
Böhni et al. BMC Ophthalmology (2015) 15:109 DOI 10.1186/s12886-015-0101-4 RESEARCH ARTICLE Comparison of Eylea with Lucentis as first-line therapy in patients with treatment-naïve neovascular age-related
More informationThe Era of anti- - - VEGF Kirk L. Halvorson, OD
The Era of anti- - - VEGF Kirk L. Halvorson, OD Introduction: Anti- - - Vascular Endothelial Growth Factor (Anti- - - VEGF) medication is a relatively a new line of medications used in treating a variety
More informationJennifer J. Arnold 1*, Caroline M. Markey 2, Nicol P. Kurstjens 3 and Robyn H. Guymer 4
Arnold et al. BMC Ophthalmology (2016) 16:31 DOI 10.1186/s12886-016-0207-3 STUDY PROTOCOL Open Access The role of sub-retinal fluid in determining treatment outcomes in patients with neovascular age-related
More informationNoninvasive cross-sectional imaging of the retina
IDENTIFICATION OF FLUID ON OPTICAL COHERENCE TOMOGRAPHY BY TREATING OPHTHALMOLOGISTS VERSUS A READING CENTER IN THE COMPARISON OF AGE-RELATED MACULAR DEGENERATION TREATMENTS TRIALS CYNTHIA A. TOTH, MD,*
More informationLong-term Management of AMD. Motasem Al-latayfeh, MD Assistant Prof. Ophthalmology Hashemite University Jordan
Long-term Management of AMD Motasem Al-latayfeh, MD Assistant Prof. Ophthalmology Hashemite University Jordan DEFINITION 1 Age-related macular degeneration (AMD) is a disorder of the macula characterized
More informationIntravitreal Aflibercept Injection for Neovascular Age-related Macular Degeneration
for Neovascular Age-related Macular Degeneration Ninety-SixeWeek Results of the VIEW Studies Ursula Schmidt-Erfurth, MD, 1 Peter K. Kaiser, MD, 2 Jean-François Korobelnik, MD, 3 David M. Brown, MD, 4 Victor
More informationVisual acuity outcomes at one year in a national multicentre audit of aflibercept for treatmentnaïve neovascular AMD
S p o ns o r e d F e a tu r e 1 Visual acuity outcomes at one year in a national multicentre audit of aflibercept for treatmentnaïve neovascular AMD First-year visual outcomes from a national multicentre
More informationTwo Year Outcomes of Treat And Extend Intravitreal Therapy Using Aflibercept Preferentially for Neovascular Age-Related Macular Degeneration
Zurich Open Repository and Archive University of Zurich Main Library Strickhofstrasse 39 CH-8057 Zurich www.zora.uzh.ch Year: 2018 Two Year Outcomes of Treat And Extend Intravitreal Therapy Using Aflibercept
More informationTREATMENT STRATEGIES FOR CHORIORETINAL VASCULAR DISEASES: ADVANTAGES AND DISADVANTAGES OF INDIVIDUALISED THERAPY
TREATMENT STRATEGIES FOR CHORIORETINAL VASCULAR DISEASES: ADVANTAGES AND DISADVANTAGES OF INDIVIDUALISED THERAPY *Michael W. Stewart Professor and Chairman, Mayo School of Medicine, Department of Ophthalmology,
More informationAge-related macular degeneration (AMD) and RANIBIZUMAB (Lucentis)
Aggiornamento biotecnologico: MoAb anti VEGF Age-related macular degeneration (AMD) and RANIBIZUMAB (Lucentis) Giulia Germena AMD DRY (non-neovascular) Atrophic cell death in the macula No leakage WET
More informationNeovascular age-related macular degeneration (namd) is a
REVIEW ARTICLe Recommended Guidelines for Use of Intravitreal Aflibercept With a Treat-and-Extend Regimen for the Management of Neovascular Age-Related Macular Degeneration in the Asia-Pacific Region:
More informationTreatment options for the wet form of age-related macular degeneration a perspective
Perspective Treatment options for the wet form of age-related macular degeneration a perspective Marion R. Munk 1,2, Rene Rückert 3 1 Department of Ophthalmology, Inselspital, University Hospital Bern,
More informationDespite our growing knowledge of the
OVERVIEW OF AVAILABLE TREATMENTS FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION * Carl D. Regillo, MD ABSTRACT Although potential treatments for neovascular age-related macular degeneration represent
More informationThe CATT Research Group* A bs tr ac t
The new england journal of medicine established in 1812 may 19, 2011 vol. 364 no. 20 and for Neovascular Age-Related Macular Degeneration The CATT Research Group* A bs tr ac t Background Clinical trials
More informationPhotodynamic Therapy for Choroidal Neovascularization
Photodynamic Therapy for Choroidal Neovascularization Policy Number: 9.03.08 Last Review: 10/2014 Origination: 10/2000 Next Review: 10/2015 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will
More informationThe Use of Intravitreal Aflibercept in the Treatment of Wet Type of Age Related Macular Degeneration
BMH Medical Journal 2015;2(2):31-36 Review Article The Use of Intravitreal Aflibercept in the Treatment of Wet Type of Age Related Macular Degeneration Rejith Rag, MBBS, FRCS, DO, FICO Department of Ophthalmology,
More informationThe Foundation WHAT IS THE RETINA?
Age-Related Macular Degeneration (AMD) is a deterioration of the retina and choroid that leads to a substantial loss in visual acuity (sharpness of vision). AMD is the leading cause of significant visual
More informationInternational Journal of Health Sciences and Research ISSN:
International Journal of Health Sciences and Research www.ijhsr.org ISSN: 2249-9571 Original Research Article A Multivariate Analysis of Intravitreal Injection of Anti-VEGF Bevacizumab in the Treatment
More informationVEGF Trap-Eye: New Data Confirm Successes in the Treatment of Age-related Macular Degeneration
Investor News Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Final Phase 2 Results Presented at Retina Society Meeting VEGF Trap-Eye: New Data Confirm Successes in the Treatment
More informationEffectiveness of Ranibizumab for Neovascular Age-related Macular Degeneration using Clinician Determined Retreatment Strategy
Effectiveness of Ranibizumab for Neovascular Age-related Macular Degeneration using Clinician Determined Retreatment Strategy Anupma Kumar, Jayashree N Sahni, Alexandros N Stangos, Claudio Campa, Simon
More informationMONTHLY ADMINISTERED INTRAVITREOUS PHARmacotherapy
Polypoidal Choroidal Vasculopathy Masquerading as Neovascular Age-Related Macular Degeneration Refractory to Ranibizumab ALEXANDROS N. STANGOS, JAGDEEP SINGH GANDHI, JAYASHREE NAIR-SAHNI, HEINRICH HEIMANN,
More informationAnti-VEGF drugs & CATT Results. in AMD. Apollo Hospitals, Hyderabad. Mallika Goyal, MD
Anti-VEGF drugs & CATT Results in AMD Mallika Goyal, MD Apollo Hospitals, Hyderabad Vascular Endothelial Growth Factor Napoleone Ferrara at Genentech 1989 identified & cloned the gene Protein that causes
More informationRisk factors of a reduced response to ranibizumab treatment for neovascular age-related macular degeneration evaluation in a clinical setting
Korb et al. BMC Ophthalmology 2013, 13:84 RESEARCH ARTICLE Open Access Risk factors of a reduced response to ranibizumab treatment for neovascular age-related macular degeneration evaluation in a clinical
More informationSupplement to March Ranibizumab for Visual Impairment in DME: An Overview of The Evidence SPONSORED BY NOVARTIS PHARMA AG
Supplement to March 2018 Ranibizumab for Visual Impairment in DME: An Overview of The Evidence SPONSORED BY NOVARTIS PHARMA AG Ranibizumab for Visual Impairment in DME: An Overview of The Evidence BY PROF.
More informationAflibercept for neovascular age-related macular degeneration.
Cochrane Database of Systematic Reviews Aflibercept for neovascular age-related macular degeneration (Review) SarwarS,ClearfieldE,SolimanMK,SadiqMA,BaldwinAJ,HanoutM,AgarwalA,SepahYJ,DoDV, Nguyen QD SarwarS,ClearfieldE,SolimanMK,SadiqMA,BaldwinAJ,HanoutM,AgarwalA,SepahYJ,DoDV,NguyenQD.
More informationAnti Vascular Endothelial Growth Factor Pharmacotherapy for Diabetic Macular Edema
Ophthalmic Technology Assessment Anti Vascular Endothelial Growth Factor Pharmacotherapy for Diabetic Macular Edema A Report by the American Academy of Ophthalmology Allen C. Ho, MD, Ingrid U. Scott, MD,
More informationDescription. Section: Other Effective Date: July 15, Subsection: Vision Original Policy Date: December 7, 2011 Subject: Page: 1 of 23
Last Review Status/Date: June 2015 Page: 1 of 23 Description Photodynamic therapy (PDT) is a treatment modality designed to selectively occlude ocular choroidal neovascular tissue. The therapy is a 2-step
More informationInnovation in Neovascular Age-Related Macular Degeneration: Consideration of Brolucizumab, Abicipar, and the Port Delivery System
For this Practical Retina column, Charles C. Wykoff, MD, PhD, and Brenda Zhou, BS, from Houston, Texas, were asked to comment on the innovations taking place to benefit our patients with neovascular AMD
More informationMEDICAL OPHTHALMOLOGY. Armin Wolf & Anselm Kampik
Graefes Arch Clin Exp Ophthalmol (2014) 252:647 655 DOI 10.1007/s00417-013-2562-6 MEDICAL OPHTHALMOLOGY Efficacy of treatment with ranibizumab in patients with wet age-related macular degeneration in routine
More informationDr Dianne Sharp Ophthalmologist Retina Specialists, Parnell Greenlane Clinical Centre
Dr Dianne Sharp Ophthalmologist Retina Specialists, Parnell Greenlane Clinical Centre 11:00-11:55 WS #115: The Revolution in Macular Degeneration Management 12:05-13:00 WS #127: The Revolution in Macular
More informationIntraocular Radiation Therapy for Age-Related Macular Degeneration
Intraocular Radiation Therapy for Age-Related Macular Degeneration Policy Number: 9.03.20 Last Review: 9/2014 Origination: 9/2008 Next Review: 9/2015 Policy Blue Cross and Blue Shield of Kansas City (Blue
More informationFrequency of sustained IOP elevation in patients receiving intravitreal injections of anti-vegf agents for exudative age-related macular degeneration
Frequency of sustained IOP elevation in patients receiving intravitreal injections of anti-vegf agents for exudative age-related Aim Frequency of sustained IOP elevation in patients receiving intravitreal
More informationClinical results of OPT-302 (VEGF-C/D Trap ) Combination Treatment in namd and DME
Clinical results of OPT-302 (VEGF-C/D Trap ) Combination Treatment in namd and DME Ophthalmology Innovation Summit @ AAO, October 25 2018 Megan Baldwin PhD, CEO & Managing Director Disclaimer Investment
More informationCoding Implications Revision Log. See Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Verteporfin (Visudyne) Reference Number: CP.PHAR.187 Effective Date: 03.16 Last Review Date: 02.18 Line of Business: Commercial, Medicaid Coding Implications Revision Log See Important
More informationClinical results of OPT-302 (VEGF-C/D Trap ) Combination Treatment in namd and DME
Clinical results of OPT-302 (VEGF-C/D Trap ) Combination Treatment in namd and DME Ophthalmology Innovation Summit @ AAO, October 25 2018 Megan Baldwin PhD, CEO & Managing Director Disclaimer Investment
More informationComparison of BRVO and CRVO management
Comparison of BRVO and CRVO management Francesco Bandello, MD, FEBO Department of Ophthalmology University Vita-Salute Scientific Institute San Raffaele Milan, Italy 1 Financial Disclosure Advisory Board
More informationRanibizumab and Bevacizumab for Treatment of Neovascular Age-related Macular Degeneration
and for Treatment of Neovascular Age-related Macular Degeneration Two-Year Results Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group* Writing Committee: Daniel F. Martin,
More information2/1/2017. Agenda. David F. Williams, MD, MBA. History of Current Treatment. Current Treatment/Wet AMD Anti-VEGF Drugs. History of Current Treatment
UPDATE ON CLINICAL TRIALS FOR AMD David F. Williams, MD, MBA Agenda Brief History of Current Rx Recently Completed/New CTs: Wet AMD Recently Completed/New CTs: Dry AMD Current Treatment/Wet AMD Anti-VEGF
More informationAddressing Sub-optimal Response During the Treatment of Wet AMD
JULY/AUGUST 2014 Highlights from a roundtable discussion Part 2 of 2 Addressing Sub-optimal Response During the Treatment of Wet AMD Roundtable Faculty Peter K. Kaiser, MD (Moderator) David M. Brown, MD
More informationCENTENE PHARMACY AND THERAPEUTICS NEW DRUG REVIEW 2Q17 April May
BRAND NAME Lucentis GENERIC NAME ranibizumab MANUFACTURER Genentech, Inc. DATE OF APPROVAL June 30, 2006 PRODUCT LAUNCH DATE July 13, 2006 REVIEW TYPE Review type 1 (RT1): New Drug Review Full review of
More informationOPT-302: VEGF-C/D trap for Eye Diseases. Ophthalmology Innovation ASRS, August Megan Baldwin PhD, CEO & Managing Director
OPT-32: VEGF-C/D trap for Eye Diseases Ophthalmology Innovation Summit @ ASRS, August 1 217 Megan Baldwin PhD, CEO & Managing Director Disclaimer Investment in Opthea Limited ( Opthea ) is subject to investment
More informationEPIRETINAL MEMBRANES IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. Effect on Outcomes of Anti-vascular Endothelial Growth Factor Therapy
EPIRETINAL MEMBRANES IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION Effect on Outcomes of Anti-vascular Endothelial Growth Factor Therapy EMINE ESRA KARACA, MD,* BURÇIN KEPEZ YILDIZ, MD, MEHMET ÖZGÜR
More informationDATE: 11 March 2014 CONTEXT AND POLICY ISSUES
TITLE: Long-Term Use of Ranibizumab for the Treatment of Age-Related Macular Degeneration: A Review of the Clinical and Cost-Effectiveness and Guidelines DATE: 11 March 2014 CONTEXT AND POLICY ISSUES Age-related
More informationResults of a Treat-and-Eextend Regimen of Intravitreal Ranibizumab Injection for Macular Edema due to Branch Retinal Vein Occlusion
Original Article http ://escholarship.lib.okayama-u.ac.jp/amo/ Results of a Treat-and-Eextend Regimen of Intravitreal Ranibizumab Injection for Macular Edema due to Branch Retinal Vein Occlusion Mika Hosogi,
More informationOutcomes of Persistently Active Neovascular Age-Related Macular Degeneration. Treated with VEGF Inhibitors: Observational Study data.
Outcomes of Persistently Active Neovascular Age-Related Macular Degeneration Treated with VEGF Inhibitors: Observational Study data. Daniel Barthelmes 1,9, Richard Walton 1, Anna E Campain 1, Judy M Simpson
More informationDescription. Section: Other Effective Date: July 15, Subsection: Vision Original Policy Date: September 13, 2011 Subject: Page: 1 of 18
Last Review Status/Date: June 2014 Page: 1 of 18 Description Angiogenesis inhibitors (e.g., ranibizumab, bevacizumab, pegaptanib, aflibercept) are being evaluated for the treatment of disorders of choroidal
More informationA Little Physics. How Does It Work? Radiation Therapy for Choroidal Neovascularisation in AMD A Review. => cell death
Radiation Therapy for Choroidal Neovascularisation in AMD A Review Jen Anikina ST4 Hillingdon Hospital A Little Physics One gray is the absorption of one joule of ionizing radiation energy per kilogram
More informationUpdates and Controversies
Updates and Controversies Philippine Journal of OPHTHALMOLOGY Vascular endothelial growth factor (VEGF) and inflammation. VEGF-A circulates normally in the body and is essential in endothelial cell growth.
More informationEfficacy of Anti-VEGF Agents in the Treatment of Age-Related Macular Degeneration
Efficacy of Anti-VEGF Agents in the Treatment of Age-Related Macular Degeneration Marilita M. Moschos Abstract- Purpose: To evaluate by OCT and mf-erg the macular function in eyes with CNV due to ARMD
More informationEvolution in Screening: Benefits of identifying and managing disease earlier
Evolution in Screening: Benefits of identifying and managing disease earlier Bora Eldem, Prof.,MD.,FEBO, Professor of Ophthalmology, Faculty of Medicine, Hacettepe University, Turkey Survey methodology
More informationBayer and Regeneron start clinical Phase III trial to extend ophthalmology research & development program for VEGF Trap- Eye in Asia
Investor News Not intended for U.S. Media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com VEGF Trap-Eye in myopic choroidal neovascularization: Bayer and Regeneron start clinical
More informationBiomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2015; 159:XX.
The efficacy of ranibizumab treatment in clinical practice in patients with the wet form of age-related macular degeneration. The results of the Czech National Registry Oldrich Chrapek a, Jiri Jarkovsky
More informationDigital Journal of Ophthalmology Digital Journal of Ophthalmology. Abstract
Original Articles Combined intravitreal ranibizumab and verteporfin photodynamic therapy versus ranibizumab alone for the treatment of age-related macular degeneration Rosalia Giustolisi, MD, Nicoletta
More informationEU Regulatory workshop Ophthalmology clinical development and scientific advice. Industry view on DME and macular edema secondary to RVO
EU Regulatory workshop Ophthalmology clinical development and scientific advice. Industry view on DME and macular edema secondary to RVO Yehia Hashad, M.D. Vice President and Global Therapeutic Area Head
More informationRoundtable Faculty: September Peter Kaiser, MD (Moderator) Justis Ehlers, MD Seenu Hariprasad, MD Atul Jain, MD Jason Slakter, MD
Insights on Switching Anti-VEGF Agents for Optimal AMD Treatment Highlights of a roundtable discussion held during the 2013 meeting of the Association for Research in Vision and Ophthalmology (ARVO) September
More information